Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy

A small proportion of chronic myeloid leukemia patients treated with interferon-α (IFN-α) monotherapy are able to discontinue the treatment without disease relapse although residual leukemia cells are present. Recently, we showed that these patients have increased amount of NK-cells and a distinct blood cytokine profile. We now aimed to study the function of NK- and T-cells in order to understand the role of the immune system in maintaining the treatment response after IFN-α discontinuation. The study included 13 patients: 5 patients were still treated with IFN-α monotherapy (IFN-ON, median treatment time 163 months) and 8 had stopped the treatment successfully (IFN-OFF, median time without therapy 42 months). Detailed immunophenotype and cytokine production of NK- and T-cells was analyzed with flow cytometry. In addition, the cytotoxicity of NK-cells was studied using K562 as target cells and both the degranulation and direct killing was measured. Compared to healthy controls, IFN-OFF patients had increased proportion of CD4+ effector memory (CCR7−CD45RA−; median 23% vs. healthy 16%, p = 0.009) and CD8+ central memory T-cells (CCR7+CD45RA−; median 26% vs. healthy 14%, p = 0.004). Further, upon stimulation the IFN-γ/TNF-α cytokine secretion by CD4+ T-cells was significantly enhanced in IFN-OFF patients (median 13.7% vs. healthy 7.8%, p = 0.01), and CD4+ effector and central memory cells were the main cytokine producers. No similar increase was observed in IFN-ON group (6.5%). In addition, the proportion of NK-cells was significantly increased in IFN-OFF patients (median IFN-OFF 24%, healthy 13%, p = 0.04), but their direct killing of K562 cells was impaired. The cytotoxicity of NK-cells was also diminished in IFN-ON patients. To conclude, in addition to elevated NK-cell count, IFN-OFF patients have increased amount of memory T-cells, which are able to induce strong cytokine response upon stimulation. This activity may contribute to the maintenance of prolonged remission after successful IFN-α discontinuation.

[1]  S. Mustjoki,et al.  Imatinib and pegylated IFN‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response , 2014, European journal of haematology.

[2]  S. Mustjoki,et al.  Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy , 2014, Leukemia & lymphoma.

[3]  W. M. Smit,et al.  Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). , 2013, European journal of cancer.

[4]  K. Campbell,et al.  Natural killer cell biology: an update and future directions. , 2013, The Journal of allergy and clinical immunology.

[5]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[6]  Sheng-hao Wu,et al.  [A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α]. , 2012, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[7]  L. Lanier,et al.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. , 2012, Blood.

[8]  M. Tomonaga,et al.  Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa , 2012, International Journal of Hematology.

[9]  Arnon Nagler,et al.  Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. , 2011, Blood.

[10]  S. Mustjoki,et al.  Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile , 2011, PloS one.

[11]  P. J. Norris,et al.  Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection , 2011, Proceedings of the National Academy of Sciences.

[12]  Joseph C. Sun,et al.  Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection , 2011, The Journal of experimental medicine.

[13]  Claude Preudhomme,et al.  Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. , 2010, The New England journal of medicine.

[14]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[15]  A. Thiel,et al.  CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. , 2010, Blood.

[16]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[17]  Pamela A McCombe,et al.  The effect of ageing on human lymphocyte subsets: comparison of males and females , 2010, Immunity & Ageing.

[18]  Martin C. Müller,et al.  Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Izutsu,et al.  CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response. , 2009, Leukemia research.

[20]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2009, Leukemia.

[21]  Joseph C. Sun,et al.  Adaptive Immune Features of Natural Killer Cells , 2009, Nature.

[22]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[23]  Yuping Deng,et al.  Age-Related Impaired Type 1 T Cell Responses to Influenza: Reduced Activation Ex Vivo, Decreased Expansion in CTL Culture In Vitro, and Blunted Response to Influenza Vaccination In Vivo in the Elderly1 , 2004, The Journal of Immunology.

[24]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[25]  B. Simões,et al.  Immunological Effects of Interferon-alpha on Chronic Myelogenous Leukemia , 2003, Leukemia & lymphoma.

[26]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Baccarani,et al.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. , 2001, Blood.

[28]  G. Daley,et al.  Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. , 2001, Blood.

[29]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[30]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[31]  M. Fricová,et al.  [Interferon alpha in the treatment of chronic myeloid leukemia]. , 1996, Vnitrni lekarstvi.

[32]  G. Pawelec,et al.  Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. , 1995, Leukemia & lymphoma.

[33]  Emil,et al.  Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. , 1992, Blood.

[34]  R. Kurzrock,et al.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. , 1991, Annals of internal medicine.

[35]  J. Forman,et al.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes , 1982, The Journal of experimental medicine.

[36]  Haoyu Sun,et al.  Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. , 2014, Cytokine.

[37]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[38]  S. Rosenberg,et al.  Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. , 2005, Blood.

[39]  Martin C. Müller,et al.  Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia , 2003 .

[40]  C. Barthe,et al.  Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Kantarjian,et al.  Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia , 1998, Leukemia.

[42]  M. Talpaz,et al.  Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon , 1998, Leukemia.